The estimated Net Worth of Asset Management, Lp Chen B... is at least $237 Миллион dollars as of 14 May 2019. Asset B owns over 23,268 units of Turning Point Therapeutics Inc stock worth over $237,331,116 and over the last 6 years Asset sold TPTX stock worth over $0.
Asset has made over 2 trades of the Turning Point Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Asset exercised 23,268 units of TPTX stock worth $50,957 on 14 May 2019.
The largest trade Asset's ever made was buying 400,000 units of Turning Point Therapeutics Inc stock on 22 April 2019 worth over $7,200,000. On average, Asset trades about 141,089 units every 7 days since 2019. As of 14 May 2019 Asset still owns at least 3,122,367 units of Turning Point Therapeutics Inc stock.
You can see the complete history of Asset B stock trades at the bottom of the page.
Over the last 6 years, insiders at Turning Point Therapeutics Inc have traded over $45,947,838 worth of Turning Point Therapeutics Inc stock and bought 2,385,408 units worth $60,168,920 . The most active insiders traders include Plc Gsk, Patrick Machado и Advisors Llc Orbi Med Capit.... On average, Turning Point Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,727,594. The most recent stock trade was executed by Paolo Tombesi on 27 July 2022, trading 1,183 units of TPTX stock currently worth $88,654.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Turning Point Therapeutics Inc executives and other stock owners filed with the SEC include: